country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-183374

Copy Link Print Information

NYM074

NYM074 is a carbonic anhydrase IX (CAIX) ligand. NYM074 binds specifically to human CAIX to enable targeted radionuclide delivery. NYM074 supports dual radiolabeling with ⁶⁸Ga for positron emission tomography (PET) imaging and ¹⁷⁷Lu for radionuclide applications. NYM074 can be used for the research of clear cell renal cell carcinoma.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

화학식: C₄₁H₅₉N₁₁O₁₂S₂
분자량:962.10

보관:

Please store the product under the recommended conditions in the Certificate of Analysis.

NYM074 Chemical Structure

Amount: USD 0.00

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

Use of MCE Products

One-Stop Platform：From Independent R&D to Pilot-Scale Production

Biological Activity
- 제품 설명
- IC₅₀ & Target
- In Vitro
- Parmacokinetics
- In Vivo
Chemical Information
순도&문서
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

제품 설명

IC₅₀ & Target

^[1]

hCA IX

All Carbonic Anhydrase Isoforms :

All Radionuclide-Drug Conjugates (RDCs) Isoforms :

In Vitro

NYM074 (0.5-500 nM; 240 s) binds with high, selective affinity to recombinant human CAIX (K_d = 0.65 nM) compared to human CAII and CAXII in an in vitro SPR assay^[1].
NYM074, when radiolabeled as [⁶⁸Ga]Ga-NYM074, is selectively taken up by CAIX-positive OS-RC-2 cells in an in vitro assay, with uptake significantly reduced by 100-fold excess unlabeled NYM074, while CAIX-negative PC-3 cells show minimal uptake^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Parmacokinetics

Species	Dose	Route	T_1/2	T_max	V	CL	MRT_0-t	MRT_0-inf	V_ss
Mice^[1]	28.57 μg/kg	i.v.	3.3 h	0.02 h	2.54 L/kg	0.53 L/h/kg	1.32 h	5.03 h	2.69 L/kg

In Vivo

NYM074 (2 mCi; i.v.; single dose, two doses with 7-day interval; up to 30 days) achieves a maximum tumor growth inhibition of 73.90% in OS-RC-2 ccRCC xenograft mice with excellent tolerability following radiolabelled with ¹⁷⁷Lu^[1].
NYM074 (0.1 mCi; i.v.; single dose) achieves peak tumor uptake of 9.57 %ID/g at 60 minutes in OS-RC-2 ccRCC xenograft mice following radiolabelled with ⁶⁸Ga^[1].
NYM074 (0.3 mCi; i.v.; single dose) exhibits high and prolonged tumor uptake of 29.15 %ID/g at 4 hours in OS-RC-2 ccRCC xenograft mice following radiolabelled with ¹⁷⁷Lu, with a calculated tumor absorbed dose of 296 mGy/MBq^[1].
NYM074 (28.57 μg/kg; i.v.; single dose) exhibits a half-life of 3.3 hours and predominant renal excretion in healthy ICR mice following radiolabelled with ⁶⁸Ga, with highest uptake in kidneys and liver^[1].
NYM074 (2 mCi; i.v.; single dose; 14 days) does not induce notable histopathological changes in major organs of healthy ICR mice following radiolabelled with ¹⁷⁷Lu^[1].
NYM074 (0.3 mCi; i.v.; single dose) exhibits predominant renal excretion with highest uptake in kidneys and liver in healthy ICR mice following radiolabelled with ¹⁷⁷Lu, with minimal bone uptake indicating in vivo stability^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

BALB/c nude mice (female, 6-8 weeks, 18-22 g, subcutaneously inoculated with OS-RC-2 tumor cells)^[1]
Dosage:

2 mCi
Administration:

i.v.; single dose or two doses with 7-day interval; up to 30 days
Result:

Resulted in a final tumor volume of 1248.89 mm³, a T/C ratio of 65.24%, and a tumor growth inhibition (TGI) of 40.47% compared to the saline control group.
Resulted in a final tumor volume of 547.55 mm³, a T/C ratio of 25.33%, and a TGI of 73.90% (P < 0.001 vs. saline).
Showed stable body weights with <5% loss, with no significant difference from the vehicle control group.

Animal Model:

BALB/c nude mice (female, 6-8 weeks, 18-22 g, subcutaneously inoculated with OS-RC-2 tumor cells)^[1]
Dosage:

0.1 mCi
Administration:

i.v.; single dose
Result:

Showed time-dependent tumor uptake, peaking at 9.57 %ID/g at 60 minutes post-injection.
Reached a tumor-to-muscle ratio of 8.25 at 60 minutes.
Reduced tumor uptake by 78.69% with co-injection of 10 mg/kg acetazolamide, confirming specific CAIX targeting.
Decreased renal uptake over time from 19.85 %ID/g at 10 minutes to 13.74 %ID/g at 120 minutes.

Animal Model:

BALB/c nude mice (female, 6-8 weeks, 18-22 g, subcutaneously inoculated with OS-RC-2 tumor cells)^[1]
Dosage:

0.3 mCi
Administration:

i.v.; single dose
Result:

Showed sustained tumor retention, with ex vivo uptake of 29.15 %ID/g at 4 hours and 3.28 %ID/g at 48 hours post-injection.
Achieved a calculated tumor absorbed dose of 296 mGy/MBq.
Declined liver and kidney radioactivity significantly over time.

Animal Model:

ICR mice (6-week-old)^[1]
Dosage:

28.57 μg/kg
Administration:

i.v.; single dose
Result:

Showed highest uptake in kidneys (11.31 %ID/g at 15 minutes; 13.97 %ID/g at 60 minutes; 13.05 %ID/g at 120 minutes; 11.04 %ID/g at 240 minutes) and liver (9.63 %ID/g at 15 minutes; 9.70 %ID/g at 60 minutes; 9.76 %ID/g at 120 minutes; 8.47 %ID/g at 240 minutes).
Achieved a half-life (T_1/2) of 3.3 hours, moderate clearance rate (CL_obs = 0.53 (L/h)/kg), and mean residence time (MRT(0-inf)_obs) of 5.03 hours.
Reached effective absorbed doses for male/female mice of 0.012/0.015 mSv/MBq.

Animal Model:

ICR mice (healthy adult, 20-25 g, half male/half female)^[1]
Dosage:

2 mCi
Administration:

i.v.; single dose; 14 days
Result:

Revealed intact tissue architecture and normal cellular morphology in kidneys, liver, spleen, lungs, and heart.
Showed no significant inflammation, necrosis, fibrosis, hemorrhage, or other treatment-related pathological alterations.

Animal Model:

ICR mice^[1]
Dosage:

0.3 mCi
Administration:

i.v.; single dose
Result:

Showed highest uptake in kidneys (52.78 %ID/g at 1 hour; 34.36 %ID/g at 6 hours; 5.67 %ID/g at 24 hours; 4.64 %ID/g at 48 hours) and liver (34.25 %ID/g at 1 hour; 28.53 %ID/g at 6 hours; 1.93 %ID/g at 24 hours; 0.47 %ID/g at 48 hours).
Showed uptake in brain, spleen, bone, and bone marrow of <0.25 %ID/g at all time points.
Reached whole-body effective doses for male/female mice of 0.026/0.035 mSv/MBq.

Chemical Information

분자량 962.10
화학식 C₄₁H₅₉N₁₁O₁₂S₂
SMILES

O=C(CCCCC(N[C@@H](CC1=CC(C=CC=C2)=C2C=C1)C(NCCCCNC(CN3CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC3)=O)=O)=O)NC4=NN=C(S(=O)(N)=O)S4
선적

Room temperature in continental US; may vary elsewhere.
보관

Please store the product under the recommended conditions in the Certificate of Analysis.

순도&문서

Handling Instructions (2659 KB)

References

[1]. Li S, et al. Development and preclinical evaluation of NYM074 as a novel Theranostic ligand targeting carbonic anhydrase IX in renal cell carcinoma. Bioorg Chem. 2026;176:109890. [Content Brief]

Calculators

몰농도 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

농도 희석 계산기

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

견적 받기 해외재고보유

Other size

견적 받기

Amount: USD 0.00

Biological Activity
- 제품 설명
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
순도&문서
References

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

상품명:
CAS No.:
Species:
Purity:
수량:

NYM074

All Carbonic Anhydrase Isoforms

All Radionuclide-Drug Conjugates (RDCs) Isoforms